Silvia Vázquez Fernández

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population

Javier Fernández-Mateos, Raquel Seijas-Tamayo, Miren Taberna et al. · Oral Oncology · 2016 · 25 citations · Full text

Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location

Raquel Seijas-Tamayo, Javier Fernández-Mateos, Juan Carlos Adansa Klain et al. · Clinical & Translational Oncology · 2016 · 19 citations

Epidemiology, Cancer Risk, Cancer Epidemiology +13

Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study

E. del Barco, Juan Carlos Adansa Klain, Silvia Vázquez Fernández et al. · Oral Oncology · 2016 · 17 citations

Neck Cancer, Neoadjuvant Therapy, Medicine +8